Related Experiment Video

Updated: Jul 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The 2006 Canadian dyslipidemia guidelines will prevent more deaths while treating fewer people--but should they be

Douglas G Manuel1, Sarah Wilson, Sarah Maaten

  • 1Institute for Clinical Evaluative Sciences, Faculty of Medicine, University of Toronto, Ontario, Canada. doug.manuel@ices.on.ca

The Canadian Journal of Cardiology
|August 8, 2008
PubMed

Insights

The 2006 Canadian dyslipidemia guidelines recommend statin treatment more efficiently than the 2003 version. This updated guideline prevents more coronary artery disease (CAD) deaths with fewer prescriptions.

Area of Science:

  • Cardiology and Public Health

Background:

  • Clinical guidelines impact large populations and resources, necessitating evaluation of population-level benefits, harms, and costs.
  • Dyslipidemia guidelines in many countries incorporate these population-specific perspectives.

Purpose of the Study:

  • To compare the effectiveness and efficiency of the 2003 and 2006 Canadian dyslipidemia guidelines for statin therapy.
  • To assess the impact on reducing coronary artery disease (CAD) deaths in the Canadian population.

Main Methods:

  • Applied 2003 and 2006 Canadian dyslipidemia guidelines to the Canadian Heart Health Survey data (n=12,300,000).
  • Analyzed data on family history, physical measurements, and fasting lipid profiles.
  • Determined the number of individuals recommended for statin treatment, potential CAD deaths avoided, and the number needed to treat (NNT) to prevent one CAD death over five years for each guideline.

Main Results:

  • The 2006 guidelines recommended statin treatment for 1.4% fewer individuals (ages 20-74) compared to the 2003 guidelines.
  • The 2006 guidelines potentially prevent 7% more CAD deaths.
  • The number needed to treat (NNT) to prevent one CAD death over five years decreased from 172 (2003) to 147 (2006).

Conclusions:

  • The 2006 Canadian dyslipidemia recommendations represent an improvement over previous versions.
  • These updated guidelines are more effective in preventing CAD events and deaths while requiring fewer statin prescriptions.
  • Future revisions should explicitly address absolute benefit and cost-effectiveness for dyslipidemia management.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...